



(51) International Patent Classification:

C07D 413/04 (2006.01) **A61P 1/16** (2006.01)
C07D 413/10 (2006.01) **A61P 9/00** (2006.01)
C07D 261/14 (2006.01) **A61P 9/10** (2006.01)
C07D 231/40 (2006.01) **A61P 11/00** (2006.01)
C07D 249/06 (2006.01) **A61P 11/06** (2006.01)
C07D 401/04 (2006.01) **A61P 29/00** (2006.01)
C07D 401/10 (2006.01) **A61P 35/00** (2006.01)
C07D 405/12 (2006.01) **A61K 31/425** (2006.01)
C07D 263/48 (2006.01) **A61K 31/426** (2006.01)
C07D 333/20 (2006.01) **C07D 275/03** (2006.01)
A61K 31/4155 (2006.01) **C07D 257/06** (2006.01)
A61K 31/42 (2006.01) **C07D 277/46** (2006.01)
A61K 31/4427 (2006.01) **C07D 307/66** (2006.01)
A61K 31/4192 (2006.01) **C07D 207/34** (2006.01)
A61K 31/381 (2006.01) **C07D 471/04** (2006.01)
A61K 31/415 (2006.01) **C07D 491/04** (2006.01)
A61K 31/421 (2006.01) **C07D 495/04** (2006.01)
A61P 19/04 (2006.01)

(21) International Application Number:

PCT/US2012/050824

(22) International Filing Date:

14 August 2012 (14.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/523,776	15 August 2011 (15.08.2011)	US
61/570,739	14 December 2011 (14.12.2011)	US
61/613,395	20 March 2012 (20.03.2012)	US
61/674,214	20 July 2012 (20.07.2012)	US

(71) Applicant (for all designated States except US): **INTERMUNE, INC.** [US/US]; 3280 Bayshore Boulevard, Brisbane, CA 94005 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUCKMAN, Brad, O.** [US/US]; 2042 Leimert Boulevard, Oakland, CA 94602

(US). **NICHOLAS, John, B.** [US/US]; 828 Sovereign Way, Redwood City, CA 94065 (US). **EMAYAN, Kumaraswamy** [US/US]; 1660 Tacoma Avenue, Berkeley, CA 94707 (US). **SEIWERT, Scott, D.** [US/US]; 719 Seymour Street, Half Moon Bay, CA 94019 (US).

(74) Agent: **HART, Daniel;** Knobbe Martens Olson & Bear LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

(57) Abstract: Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.